Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Biomea Fusion, Inc. logo

Biomea Fusion, Inc. (BMEA) Stock Ticker

NASDAQ: BMEA · Healthcare · Biotechnology
$1.32-11.41%
USD · as of 2026-09-27 · market cap $95.4M
Open BMEA in TickrDownload for iPhone

BMEA right now

Options price it to move more than 9 in 10 stocks.
Options expect by Oct 6±19.6%
Options expect by Oct 29±40.6%
Priced in for Nov 3 earnings±43.9%
IV rank (30-day)68% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full BMEA picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on BMEA
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

BMEA stock facts

Ticker symbolBMEA
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$95.4M
CEOMichael J. Hitchcock
Employees37
HeadquartersSan Carlos, CA, US
IPO date2021-04-16
Websitebiomeafusion.com

What you can see for BMEA on Tickr

Live BMEA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BMEA report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Biomea Fusion, Inc.?

The ticker symbol for Biomea Fusion, Inc. is BMEA, listed on the NASDAQ Global Select.

What is BMEA?

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase…

HomeExploreMarketLists
All pages